Pimobendan Inhibits HBV Transcription and Replication by Suppressing HBV Promoters Activity
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.837115
Abstract: Current anti-HBV therapeutic strategy relies on interferon and nucleos(t)ide-type drugs with the limitation of functional cure, inducing hepatitis B surface antigen (HBsAg) loss in very few patients. Notably, the level of HBsAg has been established… read more here.
Keywords: hbv transcription; transcription; hbv promoters; drug ... See more keywords